| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Monocyte chemotactic protein-1 mediates prostate cancer-induced bone resorption.
|
Cancer Res
|
2007
|
1.79
|
|
2
|
Metastasis suppressor gene Raf kinase inhibitor protein (RKIP) is a novel prognostic marker in prostate cancer.
|
Prostate
|
2006
|
1.78
|
|
3
|
Differential diagnosis between bacterial infection and neoplastic fever in patients with advanced urological cancer: the role of procalcitonin.
|
Int J Urol
|
2013
|
1.44
|
|
4
|
Japan Cancer of the Prostate Risk Assessment for combined androgen blockade including bicalutamide: clinical application and validation.
|
Int J Urol
|
2012
|
1.40
|
|
5
|
Prostate cancer induces bone metastasis through Wnt-induced bone morphogenetic protein-dependent and independent mechanisms.
|
Cancer Res
|
2008
|
1.34
|
|
6
|
The establishment of two paclitaxel-resistant prostate cancer cell lines and the mechanisms of paclitaxel resistance with two cell lines.
|
Prostate
|
2007
|
1.27
|
|
7
|
Activation of MCP-1/CCR2 axis promotes prostate cancer growth in bone.
|
Clin Exp Metastasis
|
2008
|
1.25
|
|
8
|
Targeting the androgen receptor with siRNA promotes prostate cancer metastasis through enhanced macrophage recruitment via CCL2/CCR2-induced STAT3 activation.
|
EMBO Mol Med
|
2013
|
1.23
|
|
9
|
Vascular endothelial growth factor contributes to the prostate cancer-induced osteoblast differentiation mediated by bone morphogenetic protein.
|
Cancer Res
|
2004
|
1.19
|
|
10
|
Current outcome of patients with ureteral stents for the management of malignant ureteral obstruction.
|
J Urol
|
2010
|
1.17
|
|
11
|
Cyclooxygenase-2 promotes prostate cancer progression.
|
Prostate
|
2002
|
1.12
|
|
12
|
Androgen receptor roles in the development of benign prostate hyperplasia.
|
Am J Pathol
|
2013
|
1.10
|
|
13
|
Androgen replacement therapy contributes to improving lower urinary tract symptoms in patients with hypogonadism and benign prostate hypertrophy: a randomised controlled study.
|
Aging Male
|
2010
|
1.06
|
|
14
|
PTHrP-induced MCP-1 production by human bone marrow endothelial cells and osteoblasts promotes osteoclast differentiation and prostate cancer cell proliferation and invasion in vitro.
|
Int J Cancer
|
2007
|
1.03
|
|
15
|
Cranial nerve deficit caused by skull metastasis of prostate cancer: three Japanese castration-resistant prostate cancer cases.
|
Int J Clin Oncol
|
2010
|
1.02
|
|
16
|
The bisphosphonate YM529 inhibits osteolytic and osteoblastic changes and CXCR-4-induced invasion in prostate cancer.
|
Cancer Res
|
2005
|
1.01
|
|
17
|
FOXA1 promotes tumor progression in prostate cancer via the insulin-like growth factor binding protein 3 pathway.
|
PLoS One
|
2012
|
0.99
|
|
18
|
A role of aryl hydrocarbon receptor in the antiandrogenic effects of polycyclic aromatic hydrocarbons in LNCaP human prostate carcinoma cells.
|
Arch Toxicol
|
2003
|
0.98
|
|
19
|
Osteoblasts induce prostate cancer proliferation and PSA expression through interleukin-6-mediated activation of the androgen receptor.
|
Clin Exp Metastasis
|
2004
|
0.98
|
|
20
|
Etiological role of human papillomavirus infection for inverted papilloma of the bladder.
|
J Med Virol
|
2011
|
0.97
|
|
21
|
Free-to-total prostate-specific antigen (PSA) ratio contributes to an increased rate of prostate cancer detection in a Japanese population screened using a PSA level of 2.1-10.0 ng/ml as a criterion.
|
Int J Clin Oncol
|
2008
|
0.95
|
|
22
|
Hormonal therapy.
|
Int J Clin Oncol
|
2007
|
0.93
|
|
23
|
Expression of human AR cDNA driven by its own promoter results in mild promotion, but not suppression, of growth in human prostate cancer PC-3 cells.
|
Asian J Androl
|
2007
|
0.93
|
|
24
|
Decreasing trend in prostate cancer with high serum prostate-specific antigen levels detected at first prostate-specific antigen-based population screening in Japan.
|
Asian J Androl
|
2014
|
0.93
|
|
25
|
Prevalence of genital Mycoplasma, Ureaplasma, Gardnerella, and human papillomavirus in Japanese men with urethritis, and risk factors for detection of urethral human papillomavirus infection.
|
J Infect Chemother
|
2011
|
0.92
|
|
26
|
Enhanced expression of organic anion transporting polypeptides (OATPs) in androgen receptor-positive prostate cancer cells: possible role of OATP1A2 in adaptive cell growth under androgen-depleted conditions.
|
Biochem Pharmacol
|
2012
|
0.91
|
|
27
|
CTEN/tensin 4 expression induces sensitivity to paclitaxel in prostate cancer.
|
Prostate
|
2010
|
0.91
|
|
28
|
Pathological effects of neoadjuvant hormonal therapy help predict progression of prostate cancer after radical prostatectomy.
|
Int J Urol
|
2003
|
0.91
|
|
29
|
Clinicopathological outcomes of clinical T1a renal cell carcinoma by tumor size.
|
Jpn J Clin Oncol
|
2011
|
0.90
|
|
30
|
Ethinylestradiol improves prostate-specific antigen levels in pretreated castration-resistant prostate cancer patients.
|
Anticancer Res
|
2010
|
0.90
|
|
31
|
Quantitative proteomics reveals that enzymes of the ketogenic pathway are associated with prostate cancer progression.
|
Mol Cell Proteomics
|
2013
|
0.90
|
|
32
|
Bone scintigraphy as a new imaging biomarker: the relationship between bone scan index and bone metabolic markers in prostate cancer patients with bone metastases.
|
Ann Nucl Med
|
2013
|
0.89
|
|
33
|
Gene therapy for prostate cancer using the cytosine deaminase/uracil phosphoribosyltransferase suicide system.
|
J Gene Med
|
2003
|
0.89
|
|
34
|
Etiologic role of human papillomavirus infection in bladder carcinoma.
|
Cancer
|
2010
|
0.89
|
|
35
|
Reversal of chemotherapy-induced leukopenia using granulocyte macrophage colony-stimulating factor promotes bone metastasis that can be blocked with osteoclast inhibitors.
|
Cancer Res
|
2010
|
0.89
|
|
36
|
Prostate cancer cells increase androgen sensitivity by increase in nuclear androgen receptor and androgen receptor coactivators; a possible mechanism of hormone-resistance of prostate cancer cells.
|
Cancer Invest
|
2007
|
0.88
|
|
37
|
Outcomes and predictive factors of prostate cancer patients with extremely high prostate-specific antigen level.
|
J Cancer Res Clin Oncol
|
2014
|
0.88
|
|
38
|
Determination of prostatic androgens in 10 mg of tissue using liquid chromatography-tandem mass spectrometry with charged derivatization.
|
Anal Bioanal Chem
|
2005
|
0.87
|
|
39
|
Prolonged treatment with three-weekly docetaxel plus daily prednisolone for metastatic castration-resistant prostate cancer: a multicenter, phase II, open-label, non-comparative, extension study in Japan.
|
Int J Clin Oncol
|
2012
|
0.87
|
|
40
|
Resistance to paclitaxel increases the sensitivity to other microenvironmental stresses in prostate cancer cells.
|
J Cell Biochem
|
2011
|
0.86
|
|
41
|
Heterogenous induction of carcinoma-associated fibroblast-like differentiation in normal human prostatic fibroblasts by co-culturing with prostate cancer cells.
|
J Cell Biochem
|
2011
|
0.85
|
|
42
|
Cryotreatment against metastatic renal cell bone tumour reduced multiple lung metastases.
|
Anticancer Res
|
2011
|
0.85
|
|
43
|
Nadir prostate-specific antigen (PSA) level and time to PSA nadir following primary androgen deprivation therapy as independent prognostic factors in a Japanese large-scale prospective cohort study (J-CaP).
|
J Cancer Res Clin Oncol
|
2014
|
0.85
|
|
44
|
Simultaneous determination of salivary testosterone and dehydroepiandrosterone using LC-MS/MS: Method development and evaluation of applicability for diagnosis and medication for late-onset hypogonadism.
|
J Chromatogr B Analyt Technol Biomed Life Sci
|
2008
|
0.84
|
|
45
|
Clinical outcomes of prostate cancer patients detected by prostate-specific antigen-based population screening in Kanazawa City, Japan.
|
Int J Urol
|
2011
|
0.84
|
|
46
|
High testosterone levels in prostate tissue obtained by needle biopsy correlate with poor-prognosis factors in prostate cancer patients.
|
BMC Cancer
|
2014
|
0.83
|
|
47
|
Determination of sulfates of androsterone and epiandrosterone in human serum using isotope diluted liquid chromatography-electrospray ionization-mass spectrometry.
|
Biomed Chromatogr
|
2005
|
0.83
|
|
48
|
Comparison of two in vivo models for prostate cancer: orthotopic and intratesticular inoculation of LNCaP or PC-3 cells.
|
Int J Urol
|
2004
|
0.82
|
|
49
|
Exogenous SPARC suppresses proliferation and migration of prostate cancer by interacting with integrin β1.
|
Prostate
|
2013
|
0.82
|
|
50
|
The effects of cyclooxygenase-2 expression in prostate cancer cells: modulation of response to cytotoxic agents.
|
J Pharmacol Exp Ther
|
2007
|
0.82
|
|
51
|
Novel HER2 selective tyrosine kinase inhibitor, TAK-165, inhibits bladder, kidney and androgen-independent prostate cancer in vitro and in vivo.
|
Int J Urol
|
2006
|
0.82
|
|
52
|
Risedronate recovers bone loss in patients with prostate cancer undergoing androgen-deprivation therapy.
|
Urology
|
2009
|
0.82
|
|
53
|
Raf kinase inhibitor protein (RKIP) deficiency decreases latency of tumorigenesis and increases metastasis in a murine genetic model of prostate cancer.
|
Prostate
|
2014
|
0.82
|
|
54
|
Downregulation of thymosin beta4 expression by androgen in prostate cancer LNCaP cells.
|
J Androl
|
2007
|
0.81
|
|
55
|
Prevalence of human papillomavirus infection in the oropharynx and urine among sexually active men: a comparative study of infection by papillomavirus and other organisms, including Neisseria gonorrhoeae, Chlamydia trachomatis, Mycoplasma spp., and Ureaplasma spp.
|
BMC Infect Dis
|
2014
|
0.81
|
|
56
|
A new luciferase reporter gene assay for the detection of androgenic and antiandrogenic effects based on a human prostate specific antigen promoter and PC3/AR human prostate cancer cells.
|
Anal Sci
|
2004
|
0.81
|
|
57
|
Trends of clinical symptoms and prognosis of middle-aged prostate cancer patients after instigation of prostate specific antigen-based population screening.
|
Prostate Int
|
2013
|
0.81
|
|
58
|
Cardiovascular and respiratory effects of the degree of head-down angle during robot-assisted laparoscopic radical prostatectomy.
|
Int J Med Robot
|
2013
|
0.81
|
|
59
|
Tranilast inhibits hormone refractory prostate cancer cell proliferation and suppresses transforming growth factor beta1-associated osteoblastic changes.
|
Prostate
|
2009
|
0.81
|
|
60
|
Bisphosphonate induces apoptosis and inhibits pro-osteoclastic gene expression in prostate cancer cells.
|
Int J Urol
|
2006
|
0.80
|
|
61
|
Role of surgical resection in adult urological soft tissue sarcoma: 25-year experience.
|
Urol Int
|
2010
|
0.80
|
|
62
|
Clinical characteristics and prostate-specific antigen kinetics of prostate cancer detected in repeat annual population screening in Japan.
|
Int J Urol
|
2013
|
0.80
|
|
63
|
Primary combined androgen blockade in localized disease and its mechanism.
|
Best Pract Res Clin Endocrinol Metab
|
2008
|
0.80
|
|
64
|
Increases in bone turnover marker levels at an early phase after starting zoledronic acid predicts skeletal-related events in patients with prostate cancer with bone metastasis.
|
BJU Int
|
2011
|
0.80
|
|
65
|
Antiandrogenic activities of diesel exhaust particle extracts in PC3/AR human prostate carcinoma cells.
|
Toxicol Sci
|
2003
|
0.79
|
|
66
|
Antiandrogenic activity of extracts of diesel exhaust particles emitted from diesel-engine truck under different engine loads and speeds.
|
Toxicology
|
2004
|
0.79
|
|
67
|
Establishment and characterization of androgen-independent human prostate cancer cell lines, LN-REC4 and LNCaP-SF, from LNCaP.
|
Int J Urol
|
2007
|
0.79
|
|
68
|
Adrenal androgen levels as predictors of outcome in castration-resistant prostate cancer patients treated with combined androgen blockade using flutamide as a second-line anti-androgen.
|
Int J Urol
|
2010
|
0.79
|
|
69
|
Simultaneous determination of androstenediol 3-sulfate and dehydroepiandrosterone sulfate in human serum using isotope diluted liquid chromatography-electrospray ionization-mass spectrometry.
|
J Chromatogr B Analyt Technol Biomed Life Sci
|
2003
|
0.79
|
|
70
|
Identification of dehydroepiandrosterone metabolites formed from human prostate homogenate using liquid chromatography-mass spectrometry and gas chromatography-mass spectrometry.
|
J Chromatogr A
|
2002
|
0.79
|
|
71
|
Cumulative probability of prostate cancer detection in biopsy according to free/total PSA ratio in men with total PSA levels of 2.1-10.0 ng/ml at population screening.
|
J Cancer Res Clin Oncol
|
2013
|
0.79
|
|
72
|
Four year clinical statistics of iridium-192 high dose rate brachytherapy.
|
Int J Urol
|
2006
|
0.79
|
|
73
|
Cumulative risk of developing prostate cancer in men with low (≤ 2.0 ng/mL) prostate-specific antigen levels: a population-based screening cohort study in Japan.
|
Int J Urol
|
2013
|
0.79
|
|
74
|
Down-regulation of calcium/calmodulin-dependent protein kinase kinase 2 by androgen deprivation induces castration-resistant prostate cancer.
|
Prostate
|
2012
|
0.78
|
|
75
|
Antitumor effect of radioimmunotherapy in a mouse model of testicular tumor with micrometastases defined by polymerase chain reaction.
|
Oncol Rep
|
2002
|
0.78
|
|
76
|
Factors predictive of oncological outcome after nephroureterectomy: comparison between laparoscopic and open procedures.
|
Anticancer Res
|
2013
|
0.78
|
|
77
|
Efficacy of combined androgen blockade with zoledronic acid treatment in prostate cancer with bone metastasis: the ZABTON-PC (zoledronic acid/androgen blockade trial on prostate cancer) study.
|
Anticancer Res
|
2013
|
0.78
|
|
78
|
Should patients with localized prostate cancer receive primary androgen deprivation therapy?
|
Nat Clin Pract Urol
|
2008
|
0.78
|
|
79
|
Hormonal therapy for prostate cancer: current topics and future perspectives.
|
Int J Urol
|
2010
|
0.77
|
|
80
|
Prospective longitudinal comparative study of health-related quality of life and treatment satisfaction in patients treated with hormone therapy, radical retropubic prostatectomy, and high or low dose rate brachytherapy for prostate cancer.
|
Prostate Int
|
2013
|
0.77
|
|
81
|
Experience with androgen deprivation therapy for prostate cancer in Japan and future perspectives.
|
Curr Cancer Drug Targets
|
2015
|
0.77
|
|
82
|
The role of percutaneous needle biopsy in differentiation of renal tumors.
|
Jpn J Clin Oncol
|
2010
|
0.77
|
|
83
|
A case of bone, lung, pleural and liver metastases from renal cell carcinoma which responded remarkably well to zoledronic acid monotherapy.
|
Jpn J Clin Oncol
|
2009
|
0.76
|
|
84
|
Selection of adjuvant intravesical therapies using the European Organization for Research and Treatment of Cancer scoring system in patients at intermediate risk of non-muscle-invasive bladder cancer.
|
J Cancer Res Clin Oncol
|
2014
|
0.76
|
|
85
|
Preliminary results of tranilast treatment for patients with advanced castration-resistant prostate cancer.
|
Anticancer Res
|
2010
|
0.76
|
|
86
|
Age-specific reference range of prostate-specific antigen and prostate cancer detection in population-based screening cohort in Japan: verification of Japanese Urological Association Guideline for prostate cancer.
|
Int J Urol
|
2014
|
0.76
|
|
87
|
Severe renal hemorrhage in a pregnant woman complicated with antiphospholipid syndrome: a case report.
|
Adv Urol
|
2011
|
0.75
|
|
88
|
Preserved renal function after percutaneous radiofrequency ablation for renal tumors: experience of a single institution.
|
Anticancer Res
|
2013
|
0.75
|
|
89
|
[Total androgen blockade].
|
Nihon Rinsho
|
2002
|
0.75
|
|
90
|
Retrospective analysis of the efficacy of two cycles of M-VAC neoadjuvant chemotherapy followed by radical cystectomy for muscle-invasive bladder cancer.
|
Anticancer Res
|
2013
|
0.75
|
|
91
|
In vitro chemosensitivity test for human genito-urinary tumors using collagen gel matrix.
|
Int J Urol
|
2005
|
0.75
|
|
92
|
Case of acute urinary retention as a result of non-steroidal anti-inflammatory drugs.
|
Int J Urol
|
2007
|
0.75
|
|
93
|
[Current status and future prospects of endocrine therapy].
|
Nihon Rinsho
|
2011
|
0.75
|
|
94
|
Final results of a phase II study of S-1 in patients with cytokine-refractory metastatic renal cell carcinoma.
|
Jpn J Clin Oncol
|
2013
|
0.75
|
|
95
|
Potential benefits of combining cytosine deaminase/5-fluorocytosine gene therapy and irradiation for prostate cancer: experimental study.
|
Int J Urol
|
2002
|
0.75
|
|
96
|
[Clinical implications of bisphosphonate for bone metastases of prostate cancer].
|
Nihon Rinsho
|
2007
|
0.75
|
|
97
|
[Update of treatment for prostate cancer].
|
Gan To Kagaku Ryoho
|
2013
|
0.75
|
|
98
|
[Testosterone synthesis].
|
Nihon Rinsho
|
2006
|
0.75
|
|
99
|
Effects of dutasteride on lower urinary tract symptoms and general health in men with benign prostatic hypertroplasia and hypogonadism: a prospective study.
|
Aging Male
|
2013
|
0.75
|
|
100
|
The effectiveness of interferon-alpha subtypes alternation for metastasis from renal cell carcinoma.
|
Biomed Res
|
2012
|
0.75
|
|
101
|
Efficacy of androgen deprivation therapy for localized prostate cancer: analysis of pT0 evaluated by radical prostatectomy specimen.
|
Anticancer Res
|
2013
|
0.75
|
|
102
|
Cumulative probability of prostate cancer detection using the international prostate symptom score in a prostate-specific antigen-based population screening program in Japan.
|
Asian Pac J Cancer Prev
|
2014
|
0.75
|
|
103
|
[Role of adrenal androgen in prostate cancer].
|
Nihon Rinsho
|
2016
|
0.75
|
|
104
|
Clinical results of iridium-192 high dose rate brachytherapy with external beam radiotherapy.
|
Jpn J Clin Oncol
|
2010
|
0.75
|
|
105
|
[New inhibitors of adrenal androgen synthesis enzymes].
|
Nihon Rinsho
|
2014
|
0.75
|
|
106
|
High-dose chemotherapy with peripheral blood stem cell transplantation for advanced testicular cancer.
|
Int J Urol
|
2002
|
0.75
|
|
107
|
Successful treatment for metastases from renal cell carcinoma with alternation of interferon-alpha subtypes.
|
Int J Clin Oncol
|
2010
|
0.75
|
|
108
|
The 7th American Urological Association and the Japanese Urological Association international affiliate society meeting.
|
Int J Urol
|
2012
|
0.75
|
|
109
|
[History and current status of endocrine therapy (hormonal therapy) for prostate cancer: General consideration].
|
Nihon Rinsho
|
2016
|
0.75
|
|
110
|
Myelodysplastic syndrome treated effectively with testosterone enanthate.
|
Int J Urol
|
2011
|
0.75
|
|
111
|
[Bone and Men's Health. Hormonal therapy and bone loss in prostate cancer].
|
Clin Calcium
|
2010
|
0.75
|
|
112
|
Repression of cell proliferation and androgen receptor activity in prostate cancer cells by 2'-hydroxyflavanone.
|
Anticancer Res
|
2013
|
0.75
|